Figure 6. MAPK were not involved in estrogen-altered cell growth in WT-SMCs and CSE-KO-SMCs.

WT-SMCs (A) and CSE-KO-SMCs (B) were pretreated with 10 µM U0126 (a MEK/ERK inhibitor), or 10 µM SB 203580 (a p38 MAPK inhibitor), or 10 µM SP 600125 (a JNK inhibitor) for 30 min followed by 100 nM estrogen for additional 72 h. The cell viability was evaluated by MTT assay. The data were from four independent experiments. * p<0.05 vs. control group; ^# p<0.05 vs. estrogen group.